Protein Kinase Inhibitors: all 15,278 studies that test it

Page 51 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate CancerTerminatedNCT01717898Phase 1/2Results posted
• Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT01716715Phase 2Results posted
• Mass Balance, Pharmacokinetics and Metabolism Study of AlisertibCompletedNCT01714947Phase 1Results posted
• The Effect of Sorafenib on Portal PressureCompletedNCT01714609Phase 2Results posted
• A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset SeizuresCompletedNCT01713946Phase 3Results posted
• Oral Bioavailability and Mass Balance Trial With PimasertibCompletedNCT01713036Phase 1Results posted
• Ruxolitinib for Adult T-Cell LeukemiaTerminatedNCT01712659Phase 1/2Results posted
• TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.CompletedNCT01711658Phase 2Results posted
• BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell LeukemiaCompletedNCT01711632Phase 2Results posted
• A Study in Participants With Moderate to Severe Rheumatoid ArthritisCompletedNCT01711359Phase 3Results posted
• A Study in Moderate to Severe Rheumatoid ArthritisCompletedNCT01710358Phase 3Results posted
• Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque PsoriasisCompletedNCT01710046Phase 2Results posted
• A Study Of CP-690,550 In Stable Kidney Transplant PatientsCompletedNCT01710033Phase 1Results posted
• Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal DiseaseCompletedNCT01710020Phase 1Results posted
• Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid TumorsCompletedNCT01709435Phase 1Results posted
• Pharmacokinetics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Tacrolimus ToxicityTerminatedNCT01709136Phase 2/3Results posted
• Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung CancerActive, not recruitingNCT01708954Phase 2Results posted
• A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid TumorsTerminatedNCT01708161Phase 1/2Results posted
• Cabozantinib in Men With Castration-Resistant Prostate CancerTerminatedNCT01703065Phase 2Results posted
• A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk MyelodysplasiaTerminatedNCT01701375Phase 1Results posted
• Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By SurgeryTerminatedNCT01701037Phase 2Results posted
• Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast CancerCompletedNCT01698918Phase 2Results posted
• Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)CompletedNCT01698905Phase 2Results posted
• Neoadjuvant BKM120 in High-risk Prostate CancerTerminatedNCT01695473Phase 2Results posted
• A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for NephrectomyCompletedNCT01693822Phase 2Results posted
• Safety and Efficacy of BKM120 in Relapsed and Refractory NHLCompletedNCT01693614Phase 2Results posted
• Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)CompletedNCT01693601Phase 1/2Results posted
• Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous MelanomaCompletedNCT01693068Phase 2Results posted
• Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical TrialCompletedNCT01692496Phase 2Results posted
• A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic MelanomaCompletedNCT01689519Phase 3Results posted
• Cabozantinib for Advanced Urothelial CancerCompletedNCT01688999Phase 2Results posted
• Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by SurgeryCompletedNCT01688973Phase 2Results posted
• Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast CancerCompletedNCT01688609Phase 2Results posted
• Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular CarcinomaCompletedNCT01687673Phase 2Results posted
• LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung CancerCompletedNCT01685138Phase 2Results posted
• LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and CrizotinibCompletedNCT01685060Phase 2Results posted
• A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast CancerCompletedNCT01684215Phase 2Results posted
• Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate CancerCompletedNCT01683994Phase 1/2Results posted
• A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney DiseaseCompletedNCT01683409Phase 2Results posted
• Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K MutationCompletedNCT01682213Phase 2Results posted
• Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).CompletedNCT01682083Phase 3Results posted
• Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate SodiumCompletedNCT01680861Phase 3Results posted
• Investigation of Drug-drug Interaction of Nintedanib and Ketoconazole in Healthy Male VolunteersCompletedNCT01679613Phase 1Results posted
• BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract CancerTerminatedNCT01679405Phase 1Results posted
• Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine TumorsCompletedNCT01678664Phase 2Results posted
• A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent SubjectsCompletedNCT01677741Phase 1/2Results posted
• Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal CancerCompletedNCT01676714Phase 2Results posted
• S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast CancerActive, not recruitingNCT01674140Phase 3Results posted
• Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced MelanomaCompletedNCT01673854Phase 2Results posted
• A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCCTerminatedNCT01673386Phase 2Results posted
• Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform NeurofibromasCompletedNCT01673009Phase 2Results posted
• A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple MyelomaTerminatedNCT01672736Phase 1/2Results posted
• Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast CancerCompletedNCT01670877Phase 2Results posted
• BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian CancerCompletedNCT01669798Phase 2Results posted
• A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as MonotherapyTerminatedNCT01668017Phase 1Results posted
• A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT01667562Phase 3Results posted
• A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant MelanomaCompletedNCT01667419Phase 3Results posted
• A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)CompletedNCT01667133Phase 1/2Results posted
• Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01664897Phase 2Results posted
• A Study LY2228820 for Recurrent Ovarian CancerCompletedNCT01663857Phase 1/2Results posted
• A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic CancerCompletedNCT01663272Phase 1Results posted
• Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)CompletedNCT01662505Phase 1Results posted
• SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath TumorsCompletedNCT01661283Phase 2Results posted
• Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid CarcinomaCompletedNCT01661179Phase 1/2Results posted
• Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to ImatinibCompletedNCT01660906Phase 4Results posted
• Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's LymphomasCompletedNCT01660451Phase 2Results posted
• Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLLCompletedNCT01659255Phase 1Results posted
• Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic MelanomaCompletedNCT01659151Phase 2Results posted
• Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic LeukemiaTerminatedNCT01659021Phase 3Results posted
• Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With ChemotherapyCompletedNCT01658943Phase 2Results posted
• An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerCompletedNCT01658878Phase 1/2Results posted
• BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.CompletedNCT01658436Phase 2Results posted
• A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating MutationsCompletedNCT01657682Phase 2Results posted
• Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive RegimensCompletedNCT01653847Not applicableResults posted
• Alisertib in Treating Patients With Advanced or Metastatic SarcomaCompletedNCT01653028Phase 2Results posted
• Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic AdenocarcinomaCompletedNCT01652976Phase 2Results posted
• Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.CompletedNCT01652469Phase 3Results posted
• Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)TerminatedNCT01650805Phase 3Results posted
• Using mTOR Inhibitors in the Prevention of BK NephropathyCompletedNCT01649609Not applicableResults posted
• NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell CarcinomaTerminatedNCT01649180Phase 2Results posted
• Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior TherapyCompletedNCT01646021Phase 3Results posted
• Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)CompletedNCT01642186Phase 2Results posted
• A Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid ArthritisTerminatedNCT01640054Phase 2Results posted
• A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer PatientsCompletedNCT01639001Phase 3Results posted
• A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015KCompletedNCT01638013Phase 3Results posted
• Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the UterusCompletedNCT01637961Phase 2Results posted
• Everolimus in Treating Cutaneous T-cell LymphomaTerminatedNCT01637090Phase 2Results posted
• The Everolimus-Transplant Exit Strategy Trial (E-TEST)TerminatedNCT01636466Phase 3Results posted
• Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal CancerCompletedNCT01633541Phase 2Results posted
• A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORiTerminatedNCT01633060Phase 3Results posted
• Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief StudyCompletedNCT01632904Phase 3Results posted
• Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate CancerCompletedNCT01630590Phase 2Results posted
• A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast CancerCompletedNCT01629615Phase 2Results posted
• Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine TumorsTerminatedNCT01628913Phase 2Results posted
• Exemestane-RAD001-MetforminTerminatedNCT01627067Phase 2Results posted
• A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant RecipientsCompletedNCT01625377Phase 3Results posted
• Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung CancerCompletedNCT01625234Phase 1/2Results posted
• Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant RecipientsCompletedNCT01624948Phase 4Results posted
• Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast CancerCompletedNCT01622868Phase 2Results posted
• Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based ChemotherapyTerminatedNCT01622660Phase 2Results posted

← Protein Kinase Inhibitors overview